ST段抬高型心肌梗死和非ST段抬高型心肌梗死属于急性冠脉综合征组。这些疾病的特征是一个或几个冠状动脉完全或部分阻塞,导致心肌损伤或坏死。在他们的治疗中使用了各种药物,最近添加的是糖蛋白IIb/IIIa抑制剂。它们通过阻碍糖蛋白IIb/IIIa受体的活性起作用,which,反过来,防止血小板结块。此类中的一些GpIIb/IIIa抑制剂包括阿昔单抗,替罗非班,依替巴肽,罗西非班,还有Orbofiban.通过这篇全面的文献综述,我们旨在探讨这些药物的潜在不良反应,并比较这三种药物的副作用.我们通过PubMed和GoogleScholar进行了搜索,并确定了13篇与我们的纳入标准一致的文章:六篇文章利用了eptifibatide,四个与阿布昔单抗有关,和三个使用替罗非班。在85%的案例中,血小板计数严重下降,低至1000/μL,已报告。此外,注意到其他一些副作用:一个病例记录了患者身体周围出现的多个瘀伤点,两例报告弥漫性肺泡出血,一个病例描述了出血性心包炎导致的心脏压塞。我们的研究强调了密切关注和理解与这些药物在心血管治疗中的潜在缺点的关键意义。研究这些药物及其副作用的必要性也很明显,因为这将大大提高所提供治疗的质量。
ST-Elevation Myocardial Infarction and non-ST Elevation Myocardial Infarction belong to the acute coronary syndrome group of diseases. These conditions are characterized by the complete or partial blockage of one or several coronary arteries, resulting in myocardial injury or necrosis. Various medications are used in their treatment, with the most recent addition being Glycoprotein IIb/IIIa inhibitors. They work by hindering the activity of glycoprotein IIb/IIIa receptors, which, in turn, prevents the clumping of platelets. Some of the GpIIb/IIIa inhibitors available in this category include abciximab, tirofiban, eptifibatide, roxifiban, and orbofiban. With this comprehensive literature review, we aimed to explore the potential adverse effects of these medications and compare the three in terms of their side effects profile. We searched through PubMed and Google Scholar and pinpointed 13 articles aligned with our inclusion criteria: six articles utilized eptifibatide, four were related to abciximab, and three used tirofiban. In 85% of the cases, a severe drop in platelet count, reaching as low as 1000/μL, was reported. Additionally, several other side effects were noted: one case documented multiple bruising spots appearing around the patient\'s body, two cases reported diffuse alveolar hemorrhage, and one case described a cardiac tamponade resulting from hemorrhagic pericarditis. Our study highlights the crucial significance of keeping a watchful eye on and comprehending the potential drawbacks linked to these medications in cardiovascular treatment. The necessity of researching these medications and their side effects is also evident, as this will significantly enhance the quality of treatment provided.